Research programme: anti-AML monoclonal antibody - Astellas/MD Anderson Cancer Center

Drug Profile

Research programme: anti-AML monoclonal antibody - Astellas/MD Anderson Cancer Center

Alternative Names: h8F4

Latest Information Update: 19 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Class Monoclonal antibodies
  • Mechanism of Action HLA antigen modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Acute myeloid leukaemia

Most Recent Events

  • 07 Dec 2016 Astellas Pharma plans to file an IND application with the US FDA for Acute myeloid leukaemia
  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 06 Apr 2015 Astellas Pharma and MD Anderson Cancer Center sign an option agreement to develop h8F4 for Acute myeloid leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top